Medical blog
In recent years, modern drug therapies from the class of incretin agonists, such as semaglutide and tirzepatide, have redefined the way we understand and treat metabolic imbalances.
These interventions act not only on body weight, but on the fundamental mechanisms that regulate appetite, carbohydrate metabolism and energy homeostasis.
This evolution reflects an essential change in contemporary medicine: the shift from an approach centred exclusively on weight loss to one oriented towards metabolic health and long-term prevention.
Obesity is today recognized as a chronic, complex disease, characterized by systemic metabolic dysfunction. It is associated with chronic low-grade inflammation, insulin resistance and vascular dysfunction, contributing to the onset of diabetes mellitus, cardiovascular disease and metabolic hepatic steatosis.
The impact on longevity is profound. We are talking not only about lifespan, but about its quality, about the way the body functions over time.
Semaglutide, a GLP-1 analogue, acts by stimulating glucose-dependent insulin secretion, reducing glucagon secretion and slowing gastric emptying, which leads to a decrease in appetite and a reduction in caloric intake.
Tirzepatide introduces a dual mechanism, acting on GLP-1 and GIP receptors. This combined action amplifies the metabolic effects and influences the fine regulation of insulin and glucagon secretion, in a way that depends on the individual metabolic context.
The clinical data are consistent and relevant.
The studies in the STEP program demonstrated that semaglutide can produce an average weight reduction of approximately 15% of body weight, while the SURMOUNT studies showed, for tirzepatide, reductions of up to 20% in certain groups of patients.
These results are accompanied by improved insulin sensitivity, reduced metabolic inflammation and optimization of the cardiometabolic profile.
The indications for these therapies are clearly defined and reflect the patient's metabolic risk.
They are generally recommended in the case of a body mass index ≥30 kg/m² or ≥27 kg/m² in the presence of comorbidities, such as arterial hypertension, dyslipidemia, diabetes or sleep apnea.
This differentiation is essential, because we are not talking about an aesthetic intervention, but about the treatment of a metabolic dysfunction.
In longevity medicine, the use of these therapies is integrated into a complex and personalized assessment.
Patient selection is based on the analysis of biomarkers, the assessment of body composition and the understanding of the individual metabolic context. It is not only weight that is relevant, but also the ratio between muscle mass and fat mass, as well as the distribution of fat, in particular visceral fat.
At Maison Longévité, this assessment is carried out through professional body composition analysis, which allows precise monitoring of the evolution and adjustment of the interventions.
The interventions are not limited to pharmacological treatment. Personalized nutrition, physical activity and sleep remain the fundamental pillars of metabolic health.
In certain contexts, complementary interventions can support metabolic function. For example, alpha-lipoic acid has been studied for its effects on oxidative stress and insulin sensitivity, contributing to the optimization of metabolic parameters.
At Maison Longévité, the approach is an integrated and personalized one. The aim is not only weight loss, but the optimization of metabolic function and the reduction of long-term risk.
Because, in essence, longevity does not mean only how much weight we lose, but how well our body functions as a whole.
Dr. Mihaela Marinescu
Specialist in Geriatrics and Gerontology,
International certification in Precision & Anti-Aging Medicine (A4M)
Our team of specialists is here to help you. Fill in the form below and we will contact you as soon as possible.
Last name
First name
Phone
Message (optional)
By pressing the "send" button, I agree to the processing of my personal data (which may also include medical data) for the purpose of the provision of services by the Maison Longévité clinic.
Article published by Maison Longévité Clinic. The information is educational and does not replace a medical consultation.
Medical content written and reviewed by Dr. Mihaela Marinescu — Specialist in Geriatrics and Gerontology · Medical Director, Maison Longévité. Last reviewed: 7 October 2026. Meet the medical team
This page is for information and education. It does not replace a medical consultation or the individual recommendations of a healthcare professional.
Book consultation
Fill in the form below and we will contact you to arrange the details of your appointment.
